Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04439708
Recruiting Observational

Biomarkers and Choroidal Neovascularization

NCT04439708 · tracked via the Priya Life Science France tracker
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Observational
Started
2020-07-06
Last updated
2026-07-07

Condition(s) studied

Choroidal NeovascularizationMineralocorticoid Excess

Investigational drug(s) / intervention(s)

Blood and aqueous humor biomarker of treatment response

Blood and aqueous humor biomarker of treatment response: Blood analyses and aqueous humor analysis

Study summary

The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: Patients of group 1: * Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration * Patients without intravitreal injection or last intravitreal injection \> 3 months * Informed signed consent Patients of group 2: * Patients without choroidal neovascularization * Patients with intraocular surgery (cataract or vitrectomy surgery) * Signed consent Exclusion Criteria: * Myocardial infarction \< 12 months * Chronic renal failure * Inflammatory disease * Infectious disease :HIV, viral hepatitis, tuberculosis * Type 1 or 2 Diabetes * Patients treated by mineralocorticoid antagonist treatment. * Type 2 or 3 choroidal neovascularization * Pregnant woman

Primary outcome measure(s)

  • biomarker analysis in blood and aqueous humor of patients with neovascularization and controls — 24 months
    Biomarker concentrations (pg/ml) will be evaluated with ELISA (Enzyme Linked ImmunoSorbent Assay).
  • biomarker analysis in blood and aqueous humor of patients with neovascularization and controls — 24 months
    Biomarker concentrations (pg/ml) will be evaluated with Mulitplex Biorad.

Trial sites (2)

FacilityCityRegionStatus
Ophtalmopole Hôpital Cochin Paris France Recruiting
Hôpital Foch Suresnes France Recruiting

More Institut National de la Santé Et de la Recherche Médicale, France trials in France

French Childhood Cancer Survivor Study Recruiting
Neural Correlates of Movement Disorders Associated With PRRT2 Related Paroxysmal Kinesigenic Dyskinesia - an Ancillary Study of AMEDYST Research Recruiting
Validation and Implementation of 3T MRI Research Protocols Recruiting
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms Recruiting
Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans Recruiting

Other trials for the same condition

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04439708 on ClinicalTrials.gov ↗ ← All trials in France